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Abstract: The synthesis of new 3-cyano-2-substituted pyridines bearing various pharmacophores
and functionalities at position 2 is described. The synthesized compounds were evaluated for
their in vitro anti-cancer activities on five cancer cell lines using 5-FU as reference compound.
The results revealed that the benzohydrazide derivative 9a induced growth inhibition in human
breast cancer cell line MCF-7 with an IC50 value of 2 µM and it showed lower cytotoxicity on
MCF-12a normal breast epithelial cells. Additionally, 9a induced apoptotic morphological changes
and induced apoptosis in MCF-7 in a dose and time-dependent manner according to an enzyme
linked immunosorbent apoptosis assay which is further confirmed by a TUNEL assay. Flow
cytometric analysis indicated that 9a arrested MCF-7 cells in the G1 phase, which was further
confirmed by increased expression of p21 and p27 and reduced expression of CDK2 and CDK4.
Western blot data revealed significant upregulation of the expression of p53, Bax, caspase-3 and
down-regulation of Bcl-2, Mdm-2 and Akt. Additionally, 9a increased the release of cytochrome
c from mitochondria to cytoplasm which provokes the mitochondrial apoptotic pathway while it
showed no significant change on the expression of the death receptor proteins procaspase-8, caspase-8
and FAS. Furthermore, 9a reduced the expression of phospho AKT and β-catenin in dose dependent
manner while inhibiting the expression of migration-related genes such as matrix metalloproteinase
(MMP)-9 and vascular endothelial growth factor (VEGF). Our findings suggest that compound 9a
could be considered as a lead structure for further development of more potent apoptosis inducing
agents with anti-metastatic activities.
Keywords: 3-cyanopyridines; alkoxy substituents; MCF-7; apoptosis; p53; VEGF
1. Introduction
Breast cancer is a complex disease that comprises heterogenous tumors associated with distinctive
histological patterns and different clinical characteristics [1]. An estimated 1.7 million women will be
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diagnosed with breast cancer in 2020, a 26% increase from current levels [2]. Approximately 30% of the
women diagnosed with early-stage disease subsequently progress to metastatic breast cancer (MBC),
for which few therapeutic regimens exist [3]. Many factors contribute to the metastasis of tumor
cells; these include molecular signaling pathways, and expression of metastasis-related genes such as
matrix metalloproteinases (MMPs) [4]. Despite the advances in therapeutic modalities, MBC remains
incurable, with an estimated survival rate of about 23% over 5 years [5]. Chemotherapy resistance is
also a consistent obstacle in the management of breast cancer, where many of the initially responsive
tumors relapse and develop resistance to diverse chemotherapeutic agents [6]. Consequently, new
agents with low susceptibility to common drug resistance mechanisms are urgently needed for the
management and treatment of various forms of breast cancer.
The anticancer activity of most cytotoxic therapies which are currently used in the clinical
management of cancer patients including radiotherapy is based on their ability to induce cell death
programs such as apoptosis [7]. Apoptosis is an evolutionary conserved process characterized by a
series of morphological and biochemical changes, including cell shrinkage, nuclear DNA fragmentation
and membrane blebbing [8].
Pyridine derivatives have always constituted a subject of great interest due to the ubiquity
of pyridine in Nature and the extensive presence in the skeletal backbone of many therapeutic
agents. These derivatives were reported to possess cytotoxic [9], and anticancer activities [10–18]
in addition to topoisomerase I, II [19–21] and Src inhibitory activities [22–24]. Penclomedine (PEN1,
3,5-dichloro-4,6-dimethoxy-2-trichloromethylpyridine), is an antitumor agent which was selected for
clinical development by the NCI based on its selective antitumor activity against certain carcinomas [25].
Moreover, triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is a potent ribonucleotide
reductase inhibitor that has shown potent antiproliferative activity against several cancer cell lines [26].
Furthermore, particular interest has been focused on pyridine carbonitriles due to their remarkable
in vitro anticancer activity against a wide range of cell lines (Figure 1) [27–30]. Consequently, pyridine
carbonitrile remains a promising template for the design of a new category of chemotherapeutic agents.
Inspired by the abovementioned findings and in continuation of our efforts linked to discovering
and exploring novel lead heterocyclic structures as potent chemotherapeutic agents [31–34], new
derivatives of 3-cyano-2-substituted pyridines were synthesized for evaluation of their in vitro
anticancer activity. A literature survey revealed that incorporation of alkoxy substituents (methoxy
and/or aryloxy moieties) results in significant enhancement of antitumor activity due to magnification
of compounds’ lipophilicity [35,36]. Accordingly, the target compounds were designed so as to
comprise 3,4-dimethoxyphenyl groups at positions 4 and 6. Moreover to the best of our knowledge,
2-substituted alkoxycyanopyridines are seldom reported in the literature. Therefore, it was planned to
include variable substituents at position 2, linked to the cyanopyridine scaffold through a methyleneoxy
or acetyloxy spacer (A and B, Figure 1). Such substituents were selected so as to offer variable
electronic, lipophilic and steric environment that could influence the targeted biological activity. The
substituents include either alkyl groups of different length or biologically active pharmacophores that
are believed to be responsible for the biological significance of some reported anticancer agents such as
benzohydrazides [37,38] benzosulfohydrazides [10], dithioates [39,40] and arylhydrazones [41–43]. In
addition, incorporation of heterocyclic groups such as pyrazoles and 1,3,4-oxadiazoles (B, Figure 1) was
considered as an interesting structure variation that might impose an impact on the potential biological
activities owing to their documented chemotherapeutic activity [44–48].The in vitro antiproliferative
activity of the newly synthesized compounds was investigated against five cancer cell lines and the
effect of the most promising compound on apoptosis and expression of proteins related to cell cycle
pathways was also evaluated.
Molecules 2016, 21, 230 3 of 25
Molecules 2016, 21, 230 3 of 24 
N NHF3C
N
H
N
O
Cl
Cl
Cl
N NHF3C
N
H
Cl
O
OMe
OMe
OMe
N
CNNC
N
H
HN C6H5C6H5
N NH
N
H
H
N
O
S
R
R1
O O
N
CN
NH2
N
R3
R
R1
R2
N
CN
O
OCH3
OCH3
H3CO
OCH3
N
CN
O
OCH3
OCH3
H3CO
OCH3
R
O
R = H, CH3, CH2CH3, COCH3, 
CH2COOCH2CH3, 1,3,4-oxadiazole-2-
thione
(R= dithioates, aryl hydrazones, arylhydrazides, 
arylsulfohydrazides, pyrazole or pyrazolinone
                 A                                                                                          B
reported antitumor pyridine derivatives
reported antitumor cyanopyridines
isosteric replacement
 of NH by O
 pharmacologically 
active pharmacophores
R
isosteric replacement 
of NH by O
dimethoxyphenyl group
increases lipophilicity
dim
eth
oxy
ph
eny
l g
rou
p
inc
rea
ses
 lip
op
hili
city
dimethoxyphenyl group
increases lipophilicity
dimethoxyphenyl group
increases lipophilicity
 
Figure 1. Chemical structure of reported pyridines and cyanopyridines endowed with anticancer and 
apoptosis-inducing activities and the synthesized compounds (A,B). 
2. Results and Discussion 
2.1. Chemistry 
The synthetic strategies adopted for the synthesis of the intermediate and target compounds  
are depicted in Schemes 1–3. In Scheme 1, the cyanopyridinone 3 was prepared according to the  
Al-Saadi procedure [49] via a one-pot multicomponent reaction of 3,4-dimethoxybenzaldehyde (1), 
3,4-dimethoxyacetophenone (2), an excess of ammonium acetate and ethyl cyanoacetate in boiling 
ethanol. Heating the cyanopyridinone 3 with different alkyl halides in absolute ethanol using sodium 
ethoxide as a basic catalyst according to the Kornblum procedure [50] failed to afford the target  
O-alkylated derivatives 4a–d. However, such compounds were successfully prepared by heating the 
cyanopyridinone 3 with the appropriate alkyl halide in acetone in the presence of anhydrous K2CO3. 
Similarly, refluxing 3 with ethyl bromoacetate in dry acetone containing anhydrous K2CO3 yielded 
the corresponding ethyl acetate ester 5. Reaction of the ester 5 with hydrazine hydrate in refluxing 
ethanol resulted in the formation of the corresponding acetohydrazide 6 which was employed as key 
intermediate for synthesis of the target compounds presented in Scheme 2. 
  
Figure 1. Chemical structure of reported pyridines and cyanopyridines endowed with anticancer and
apoptosis-inducing activities and the synthesized compounds (A,B).
2. Results and Discussion
2.1. Che istry
The synthetic strategies adopted for the synthesis of the inter ediate and target co pounds
are depicted in Sche es 1–3. In Sche e 1, the cyanopyridinone 3 as prepared according to the
l-Saadi procedure [49] via a one-pot ultico ponent reaction of 3,4-di ethoxybenzaldehyde (1),
3,4-di ethoxyacetophenone (2), an excess of a oniu acetate and ethyl cyanoacetate in boiling
ethanol. eating the cyanopyridinone 3 ith different alkyl halides in absolute ethanol using sodiu
ethoxide as a basic catalyst according to the Kornblu procedure [50] failed to afford the target
O-alkylated derivatives 4a–d. o ever, such co pounds ere successfully prepared by heating the
cyanopyridinone 3 ith the appropriate alkyl halide in acetone in the presence of anhydrous K2CO3.
Si ilarly, refluxing 3 ith ethyl bro oacetate in dry acetone containing anhydrous K2CO3 yielded
the corresponding ethyl acetate ester 5. Reaction of the ester 5 ith hydrazine hydrate in refluxing
ethanol resulted in the for ation of the corresponding acetohydrazide 6 hich as e ployed as key
inter ediate for synthesis of the target co pounds presented in Sche e 2.
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Scheme 1. Synthesis of the target compounds 4, 5 and the key intermediate 6. For 4a–d: a, R = H;  
b, R = CH3; c, R = CH2CH3; d, R = COCH3; Reagents and conditions: (i) CNCH2COOEt/anhydrous 
CH3COONH4/EtOH/reflux; (ii) the appropriate alkyl halide/anhydrous K2CO3/dry acetone/reflux; (iii) 
BrCH2COOEt/anhydrous K2CO3/dry acetone/reflux; (iv) N2H4 98%/EtOH/reflux. 
In Scheme 2, the hydrazide 6 was conveniently converted to the dithioate esters 7a–d by reaction 
with carbon disulfide in DMF in presence of KOH, followed by addition of the appropriate alkyl 
halide at room temperature. Condensation of the hydrazide 6 with the appropriate aldehyde in 
boiling ethanol containing few drops glacial acetic acid afforded the respective azomethines 8a–c. It 
should be noted down here that compounds having the arylidene–hydrazide structure may exist as 
E/Z geometrical isomers about the C=N bond and as cis/trans amide conformers at the CO–NH moiety 
(Figure 2) [51,52]. In this respect, the 1H-NMR spectra of these compounds in DMSO-d6 confirmed 
their existence as E geometrical isomers, which coincides with the literature findings for analogous 
compounds containing the imine (C=N) functionality [52]. On the other hand, further interpretation 
of their 1H-NMR DMSO-d6 spectra revealed the presence of three sets of signals at δ 5.09–5.11, 5.60–5.63, 
7.96–8.0, 8.18–8.22 and δ 11.58–11.76, 11.62–11.80, attributed to the OCH2, N=CH and CO–NH groups 
of the cis and trans conformers, respectively. According to the literature, the upfield signals of the 
N=CH and CONH protons were assigned to the cis conformer of the amide structure, whereas, the 
downfield peaks were due to the trans conformer [53]. Treatment of the hydrazide 6 with benzoyl 
chloride or p-methoxybenzoyl chloride in pyridine at room temperature furnished the corresponding 
benzohydrazides 9a,b. Similarly, reaction of 6 with benzenesulfonyl chloride or p-methoxy-
benzenesulfonyl chloride gave rise to the corresponding benzenesulfohydrazides 10a,b in good yield. 
  
Scheme 1. Synthesis of the target compounds 4, 5 and the key intermediate 6. For 4a–d: a, R = H;
b, R = CH3; c, R = CH2CH3; d, R = COCH3; Reagents and conditions: (i) CNCH2COOEt/anhydrous
CH3COONH4/EtOH/reflux; (ii) the appropriate alkyl halide/anhydrous K2CO3/dry acetone/reflux;
(iii) BrCH2COOEt/anhydrous K2CO3/dry acetone/reflux; (iv) N2H4 98%/EtOH/reflux.
In Scheme 2, the hydrazide 6 was conveniently converted to the dithioate esters 7a–d by reaction
ith carbon disulfide in DMF in presence of KOH, followed by addition of the appropriate alkyl
halide at room temperature. Condensation of the hydrazide 6 with the appropriate aldehyde in
boiling ethanol containing few drops glacial acetic acid afforded the respective azomethines 8a–c.
It should be noted down here that compounds having the arylidene–hydrazide structure may exist
as E/Z geometrical isomers about the C=N bond and as cis/trans amide conformers at the CO–NH
moiety (Figure 2) [51,52]. In this respect, the 1H-NMR spectra of these compounds in DMSO-d6
confirmed their existence as E geometrical isomers, which coincides with the literature findings for
analogous compounds containing the imine (C=N) functionality [52]. On the other hand, further
interpretation of their 1H-NMR DMSO-d6 spectra revealed the presence of three sets of signals at
δ 5.09–5.11, 5.60–5.63, 7.96–8.0, 8.18–8.22 and δ 11.58–11.76, 11.62–11.80, attributed to the OCH2, N=CH
and CO–NH groups of the cis and trans conformers, respectively. According to the literature, the upfield
signals of the N=CH and CONH protons were assigned to the cis conformer of the amide structure,
whereas, the downfield peaks were due to the trans conformer [53]. Treatment of the hy razide 6
with benzoyl chloride or p-methoxybenzoyl chloride in pyridine at room temperature furnished
the corresp ding benzohydrazides 9a,b. Similarly, r action o 6 with benzenesulfonyl chloride or
p-methoxy-benzenesulfonyl chloride gave rise to the corresponding benzenesulfohydrazides 10a,b in
good yield.
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Scheme 2. Synthesis of the target compounds 7–10. For 7: a, R1 = CH3; b, R1 = C2H5; c, R1 =  
4-ethylmorpholine; d, R1 = 4-ethylpiperidine; 8 : a, R2 = 4-OCH3C6H4; b, R2 = 3,4-OCH3C6H3; c, R2 = 
3,4,5-OCH3C6H2; 9,10: a, R3= C6H5; b, R3= 4-OCH3C6H4; Reagents and conditions: (i) CS2/KOH/DMF/ 
the appropriate alkyl halide/RT; (ii) the appropriate aldehyde/EtOH/CH3COOH/reflux; (iii) benzoyl or  
p-methoxy-benzoyl chloride/dry pyridine/RT; (iv) benzenesulfonyl or p-methoxybenzenesulfonyl 
chloride/dry pyridine/RT. 
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Figure 2. E/Z geometrical isomers and cis/trans conformers of compounds 8a–c. 
In Scheme 3, condensation of the hydrazide 6 with acetylacetone or ethyl acetoacetate in 
ethanol/glacial acetic acid mixture (2:1) furnished the corresponding 3,5-dimethylpyrazole 11 and the 
pyrazolinone derivative 12, respectively. Heating 6 with methyl 2-cyano-3,3-bis(methyl-sulfanyl) 
acrylate or [bis(methylsulfanyl)methylene]malononitrile in dry DMF following reported reaction 
conditions [54] yielded the proposed 5-amino-3-methylsulfanyl-4-substituted pyrazolyl derivatives 
13a,b in moderate yield. On the other hand, refluxing 6 with carbon disulphide in ethanolic potassium 
hydroxide afforded the oxadiazolyl derivative 14. 
Scheme 2. Synthesis of the target compounds 7–10. For 7: a, R1 = CH3; b, R1 = C2H5; c, R1 = 4-ethylmorpholine;
d, R1 = 4-ethylpiperidine; 8 : a, R2 = 4-OCH3C6H4; b, R2 = 3,4-OCH3C6H3; c, R2 = 3,4,5-OCH3C6H2;
9,10: a, R3= C6H5; b, R3= 4-OCH3C6H4; Reagents and conditions: (i) CS2/KOH/DMF/the
appropriate alkyl halide/RT; (ii) the appropriate aldehyde/EtOH/CH3COOH/reflux; (iii) benzoyl or
p-methoxy-benzoyl chloride/dry pyridine/RT; (iv) benzenesulfonyl or p-methoxybenzenesulfonyl
chloride/dry pyridine/RT.
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In Scheme 3, condensation of the hydrazide 6 with acetylacetone or ethyl acetoacetate in 
ethanol/glacial acetic acid mixture (2:1) furnished the corresponding 3,5-dimethylpyrazole 11 and the 
pyrazolinone derivative 12, respectively. Heating 6 with methyl 2-cyano-3,3-bis(methyl-sulfanyl) 
acrylate or [bis(methylsulfanyl)methylene]malononitrile in dry DMF following reported reaction 
conditions [54] yielded the proposed 5-amino-3-methylsulfanyl-4-substituted pyrazolyl derivatives 
13a,b in moderate yield. On the other hand, refluxing 6 with carbon disulphide in ethanolic potassium 
hydroxide afforded the oxadiazolyl derivative 14. 
Figure 2. E/Z geometrical isomers and cis/trans conformers of compounds 8a–c.
In Scheme 3, conde i f the hydrazide 6 with acetylacetone or ethyl oacetate
in ethanol/glacial acetic acid mixture (2:1) furnished the corresponding 3,5-dimethylpyrazole
11 and the pyrazolinone derivative 12, respectively. Heating 6 with methyl 2-cyano-3,3-bis
(methyl-sulfanyl)acrylate or [bis(methylsulfanyl)methylene]malononitrile in dry DMF following
reported reaction conditions [54] yielded the proposed 5-amino-3-methylsulfanyl-4-substituted
pyrazolyl derivatives 13a,b in moderate yield. On the other hand, refluxing 6 with carbon disulphide
in ethanolic potassium hydroxide afforded the oxadiazolyl derivative 14.
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2.2. Biological Evaluation 
2.2.1. Effect of the Synthesized Compounds on Cell Viability of Different Cancer Cell Lines 
The synthesized compounds were screened for their cytotoxicity on five cancer cell lines, namely 
SK-OV-3, MCF-7, MDA-MB-231, HCT-116 and RKO, using a WST colorimetric assay. The assay 
principle is based upon the reduction of the tetrazolium salt WST-1 to formazan by cellular 
mitochondrial dehydrogenases present in viable cells. The results revealed that most of the tested 
compounds showed higher cytotoxicity than 5-FU on SK-OV-3 cells and among them compound 7c 
was the most potent as it displayed an IC50 value of 5.12 μM compared to 5-FU which showed an IC50 
value of 32.19 μM. Meanwhile, compound 9a (IC50 = 2.04 μM) was more potent than 5-FU (IC50 = 7.06 μM) 
against MCF-7 cells, whereas compounds 7c and 10b (IC50 = 7.1 and 8.12 μM, respectively) were 
nearly equipotent to 5-FU. Concerning the activity against MDA-MB-231, none of the test compounds 
showed remarkable effect on the viability of MDA-MB 231 cells. Moreover, the obtained data showed 
that compounds 4c, 4d, 7b, 7d and 9a displayed a significant effect (IC50 = 7.12–13.14 μM) on the 
viability of HCT-116 cells compared to 5-FU and among them compound 9a displayed the highest 
activity as it showed an IC50 value of 7.12 μM compared to 5-FU which showed an IC50 value of  
12.19 μM. Additionally, 9a and 9b (IC50 = 8.22 and 9.95 μM, respectively) were more potent than  
5-FU (IC50 = 20.18 μM) on RKO cells (Table 1). Taking the IC50 values as reliable criteria for comparison 
of cytotoxicity of the test compounds, it could be clearly recognized that cyanopyridines attached to 
heterocyclic moieties at the 2-position through acetyloxy or methyleneoxy spacers (compounds 11–14) 
were nearly inactive compared to cyanopyridines attached to alkyl, dithioate, arylhydrazone, 
benzohydrazide or benzosulfohydrazide groups (compounds 4–10) which showed sigificant cytotoxicity 
on the tested cell lines. Among the latter compounds the benzohydrazide derivative 9a emerged with 
the lowest IC50 in this study against MCF-7 cells compared to 5-FU. The level of cytotoxicity of 
compound 9a on MCF-12a normal breast epithelial cells was also investigated and the IC50 was found 
to be 7.5 ± 0.25 μM. Moreover, MCF-12a cells were treated with 2 μM 9a for 24 h and the results 
(Figure 3) indicated that 2 μM of 9a reduced cell viability to approximately 50% in MCF-7 cells 
Scheme 3. Synthesis of the target compounds 11–14. For 13: a, R = COOCH3; b, R = CN; Reagents and
conditions: (i) CH2(COCH3)2/EtOH/gl. CH3COOH/reflux; (ii) CH3COCH2COOC2H5/EtOH/gl.
CH3COOH/reflux; (iii) methyl 2-cyano 3,3-bis(methylsulfanyl)acrylate or 2-(bis(methylsulfanyl)-
methylene)malononitrile/DMF/reflux; (iv) CS2/KOH/EtOH/reflux.
2.2. Biological Evaluation
2.2.1. Effect of the Synthesized Compounds on Cell Viability of Different Cancer Cell Lines
The synthesized compounds were screened for their cytotoxicity on five cancer cell lines,
namely SK-OV-3, MCF-7, MDA-MB-231, HCT-116 and RKO, using a WST colorimetric assay. The
assay principle is based upon the reduction of the tetrazolium salt WST-1 to formazan by cellular
mitochondrial dehydrogenases present in viable cells. The results revealed that most of the tested
compounds showed higher cytotoxicity than 5-FU on SK-OV-3 cells and among them compound 7c was
the most potent as it displayed an IC50 value of 5.12 µM compared to 5-FU w ich showed an IC50 value
of 32.19 µ . Meanwhile, compound 9a (IC50 = 2.04 µM) was more potent than 5-FU (IC50 = 7.06 µM)
against MCF-7 cells, whereas compounds 7c and 10b (IC50 = 7.1 and 8.12 µM, respectively) were
nearly equipotent to 5-FU. Concern ng the activity against MDA-MB-231, none of th test compounds
showed remarkable effect on the viability of MDA-MB 231 ells. Moreover, the obtained data showed
that compounds 4c, 4d, 7b, 7d and 9a displayed a significant effect (IC50 = 7.12–13.14 µM) on the
viability of HCT-116 cells compared to 5-FU and a ong them compound 9a displayed the highest
activity as it showed an IC50 value of 7.12 µM compared to 5-FU which showed an IC50 value
of 12.19 µM. Additionally, 9a and 9b (IC50 = 8.22 and 9.95 µM, respectively) were more potent
than 5-FU (IC50 = 20.18 µM) on RKO cells (Table 1). Taking the IC50 values as reliable criteria for
comparison of cytotoxicity of the test compounds, it could be clearly recognized that cyanopyridines
attached to heterocyclic moieties at the 2-position through acetyloxy or methyleneoxy spacers
(compounds 11–14) were nearly inactive compared to cyanopyridines attached to alkyl, dithioate,
arylhydrazone, benzohydrazide or benzosulfohydrazide groups (compounds 4–10) which showed
sigificant cytotoxicity on the tested cell lines. Among the latter compounds the benzohydrazide
derivative 9a emerged with the lowest IC50 in this study against MCF-7 cells compared to 5-FU. The
level of cytotoxicity of compound 9a on MCF-12a normal breast epithelial cells was also investigated
and the IC50 was found to be 7.5 ˘ 0.25 µM. Moreover, MCF-12a cells were treated with 2 µM 9a for
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24 h and the results (Figure 3) indicated that 2 µM of 9a reduced cell viability to approximately 50% in
MCF-7 cells compared to approximately 74% in MCF-12a cells. The significance of viability between
MCF-7 and MCF-12a cells was calculated using SPSS non-parametric analysis of two independent
tests and the results showed statistical significance of p value 0.001. Based on the fact that 9a had less
cytotoxic effects on normal breast epithelial cells it was subjected to further studies.
Table 1. IC50 (µM) a of the synthesized 3-cyano-2-substituted pyridines against five cancer cell lines.
Compound No. SK-OV-3 b MCF-7 c MDA-MB-231 d HCT-116 e RKO f
4a 11.37 ˘ 0.72 9.08 ˘ 0.37 32.10 ˘ 0.84 20.30 ˘ 0.85 13.21 ˘ 0.77
4b 18.16 ˘ 0.98 15.52 ˘ 0.46 40.04 ˘ 1.36 26.25 ˘ 1.22 19.80 ˘ 0.37
4c 22.12 ˘ 1.32 12.28 ˘ 0.77 44.93 ˘ 1.74 10.06 ˘ 0.76 18.14 ˘ 1.03
4d 25.19 ˘ 0.76 20.30 ˘ 0.98 35.80 ˘ 0.96 13.14 ˘ 0.84 17.39 ˘ 0.44
5 10.15 ˘ 0.44 15.42 ˘ 0.94 25.12 ˘ 0.87 14.88 ˘ 0.98 22.13 ˘ 0.97
7a 9.01 ˘ 0.42 11.23 ˘ 0.22 30.10 ˘ 0.88 23.20 ˘ 0.95 11.25 ˘ 0.91
7b 12.33 ˘ 0.88 18.14 ˘ 1.76 37.87 ˘ 1.25 9.10 ˘ 0.97 15.21 ˘ 1.13
7c 5.12 ˘ 0.11 7.10 ˘ 0.44 31.73 ˘ 0.89 26.90 ˘ 0.97 20.30 ˘ 0.76
7d 10.10 ˘ 0.98 14.30 ˘ 0.95 35.53 ˘ 1.03 11.16 ˘ 1.26 24.98 ˘ 1.33
8a 14.13 ˘ 0.95 12.01 ˘ 0.96 25.34 ˘ 1.24 28.82 ˘ 0.31 12.32 ˘ 0.02
8b 10.21 ˘ 0.92 9.31 ˘ 0.98 32.26 ˘ 0.87 25.20 ˘ 0.89 14.16 ˘ 0.91
8c 12.14 ˘ 0.98 15.27 ˘ 0.74 20.31 ˘ 1.06 25.87 ˘ 0.83 16.32 ˘ 0.37
9a 9.06 ˘ 0.24 2.04 ˘ 0.13 22.34 ˘ 0.88 7.12 ˘ 0.37 8.22 ˘ 0.99
9b 7.08 ˘ 0.16 10.18 ˘ 0.92 19.27 ˘ 0.86 17.90 ˘ 0.74 9.95 ˘ 1.06
10a 11.34 ˘ 0.02 13.39 ˘ 0.98 26.82 ˘ 0.33 21.82 ˘ 0.85 12.10 ˘ 1.26
10b 9.17 ˘ 0.38 8.12 ˘ 0.47 22.44 ˘ 1.71 16.09 ˘ 1.07 15.65 ˘ 0.86
11 26.19 ˘ 0.95 >50 >50 33.90 ˘ 0.87 >50
12 20.27 ˘ 1.72 >50 >50 40.35 ˘ 1.76 >50
13a >50 >50 >50 36.30 ˘ 1.71 >50
13b >50 >50 >50 30.14 ˘ 0.76 >50
14 30.30 ˘ 1.12 >50 >50 >50 >50
5-FU 32.19 ˘ 1.03 7.06 ˘ 0.91 15.13 ˘ 0.94 12.19 ˘ 1.10 20.18 ˘ 1.16
a IC50 values are indicated as mean ˘ S.D of three independent experiments. b SK-OV-3: human ovarian
carcinoma cell line. c MCF-7: human breast adenocarcinoma cell line. d MDA-MB-231: human breast
adenocarcinoma cell line. e HCT-116: human colon carcinoma cell line. f RKO: human colon carcinoma
cell line.
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Figure 3. Cytotoxicity of compound 9a on human breast cancer cells MCF-7 and non-tumorigenic 
breast epithelial cells MCF-12a. WST-1 Assay was performed on MCF-7 and MCF-12a after treatment 
with 2 μM of compound 9a for 24 h. Each data point was an average of results from three independent 
experiments performed in triplicate and presented as M ± SD. Significant differences between the 
control and test compounds are indicated by * (* p ˂ 0.05). 
Figure 3. Cytotoxicity of compou st cancer cells MCF-7 and non-tumorigenic
breast epithelial cells MCF-12a. ST-1 s f r ed on MCF-7 and MCF-12 afte treatment
with 2 µM of compound 9a for 24 h. i t as an average of results from three ind pendent
experiments performed in triplicate an r t ˘ SD. Significant diff rences between the
control and test compounds are indicated by * (* p < 0.05).
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2.2.2. Compound 9a induces apoptosis in MCF-7 cells
Morphological Changes
The morphological changes in MCF-7 cells were followed up after treatment with different
concentrations of compound 9a (0.05, 0.1, 0.5, 2, 5 and 10 µM) for 24 h. At 0.05, 0.1 and 0.5 µM, no
morphological changes were observed, however upon treating the cells with higher concentrations
of 2, 5 and 10 µM, apoptotic features were observed, including marked apoptotic bodies and cell
shrinkage in a concentration dependent manner (Figure 4A). Untreated cells were used as a negative
control. Treatment of MCF-7 cells with DMSO 0.4% did not show any characteristics of apoptosis in
the MCF-7 cells.
TUNEL Assay
To ascertain induction of apoptosis of compound 9a on MCF-7 cells, the results were confirmed
by immune histochemical analysis using a TUNEL assay. TUNEL assay involves labeling of the
3'-hydroxyl DNA ends generated during DNA fragmentation by means of rTdT and labeled dUTP.
The localized fluorescence of apoptotic cells (labeled-dUTP) in a blue background (DAPI) for nuclei
staining or green background (FITC) was visualized using fluorescence microscope. The assay results
(Figure 4B) revealed the presence of nuclear condensation and TUNEL-positive cells (stained cells)
compared to control group.
Enzyme Linked Immunosorbent Apoptosis Assay
Compound 9a was further investigated for induction of apoptosis in MCF-7 cells using Cell
Death Detection ELISAPLUS which is used for the quantitative in vitro determination of cytoplasmic
histone-associated DNA fragments (mono- and oligonucleosomes) in apoptosing cells.
The results revealed that induction of apoptosis increased in a dose dependent fashion upon
treating MCF-7 cells with different concentrations of 9a ranging from 0.1 to 4 µM (Figure 4C-i),
additionally, apoptotic induction in MCF-7 cells increases with increasing the exposure time starting
from 3 h to 48 h (Figure 4C-ii) with optimum value at 24 h.
Flow Cytometric Analysis
Flow cytometry is considered one of the specific tools for the investigation of molecular and
morphological events occurring during cell death and cell proliferation [55]. Therefore, the effect
of compound 9a on cell cycle progression was studied by flow cytometry in propidium iodide (PI)
stained cells. The percent of cells in G1, S, G2 phases was determined after treating cells with 2 µM
of 9a for 24 h (Figure 4D). The results revealed a significant increase in the percent of G1 population
(54%) compared to control group (37%). Thus, it can be concluded that compound 9a inhibits the
proliferation of MCF-7 cells and the growth inhibition is associated with induction of G1 phase arrest.
p27 is considered as an important regulator of cell cycle [56]. To determine whether compound
9a-induced G1 arrest was associated with increased p27 level, and to study the effect on the expression
of CDK2 and CDK4 involved in cell cycle progression, cells were analyzed for the expression of these
proteins using western blot analysis after treatment with 2 µM of 9a for 24 h. The results (Figure 4E)
revealed that compound 9a increased the expression of p27 and decreased the expression of both
CDK2 and CDK4.
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Figure 4. Compound 9a-induced apoptosis in MCF-7 cells. (A) Morphological changes in MCF-7 cells 
were examined after treatment with 0.05, 0.1, 0.5, 2, 5 and 10 μM of compound 9a for 24 h. Compound 
9a induces apoptotic death including marked apoptotic bodies and cell shrinkage in a concentration 
dependent manner. Untreated cells were used as a negative control. Treatment of MCF-7 cells with 
0.4% DMSO did not show any cell death; (B) A TUNEL assay was used to confirm induction of 
apoptosis in MCF-7 cells. Cells were treated with 2 μM of 9a for 24 h. Untreated cells act as control. 
Lack of staining in control cells shows that the cells are actively proliferating, i.e., no apoptotic cell 
death and induction of apoptosis in treated cells was confirmed by the appearance of TUNEL-positive 
cells; (C) ELISA assay apoptotic cell detection. Effect of 9a on apoptosis induction in MCF-7 cells after 
treatment with different concentrations (i) and different time intervals (ii). Data are presented as  
mean ± SD (n = 3). Significant differences between the control and test compounds are indicated by * 
(* p ˂ 0.05); (D) Percent of distribution of cell cycle phases of MCF-7 breast cancer cells after treatment 
with 2 μM of 9a for 24 h. Each experiment was performed in triplicate. Data are presented as  
mean ± SD (n = 3); (E) Western blot analysis was carried out to quantify the expression levels of p27, 
CDK2 and CDK4 in treated and non-treated control cells. β-actin was used as a loading control. 
  
Figure 4. Compound 9a-induced apoptosis in MCF-7 cells. (A) Morphological changes in MCF-7
cells were examined after treatment with 0.05, 0.1, 0.5, 2, 5 and 10 µM of compound 9a for 24 h.
Compound 9a induces apoptotic death including marked apoptotic bodies and cell shrinkage in a
concentration dependent manner. Untreated cells were used as a negative control. Treatment of MCF-7
cells with 0.4% DMSO did not show any cell death; (B) A TUNEL assay was used to confirm induction
of apoptosis in MCF-7 cells. Cells were treated with 2 µM of 9a for 24 h. Untreated cells act as control.
Lack of staining in control cells shows that the cells are actively proliferating, i.e., no apoptotic cell
death and induction of apoptosis in treated cells was confirmed by the appearance of TUNEL-positive
cells; (C) ELISA assay apoptotic cell detection. Effect of 9a on apoptosis induction in MCF-7 cells
after treatment with different concentrations (i) and different time intervals (ii). Data are presented
as mean ˘ SD (n = 3). Significant differences between the control and test compounds are indicated
by * (* p < 0.05); (D) Percent of distribution of cell cycle phases of MCF-7 breast cancer cells after
treatment with 2 µM f 9a for 24 h. Each experiment was performed in triplicate. Data r r se ted as
mean ˘ S (n = 3); ( ) estern blot analysis was car ied out to quantify the expres ion levels of p27,
CDK2 and CDK4 in treated and non-treated control cells. β-actin was used as a loading control.
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Impact of 9a on Apoptotic Signaling Pathways
To further investigate the underlying pathways of 9a-induced apoptosis, we evaluated the
expression of some apoptotic and survival proteins involved in apoptosis such as p53, p21, Bax
and antiapoptotic proteins such as Bcl-2 in addition to protein kinases e.g., AKT. The tumor suppressor
protein p53 plays a critical role in inducing cell cycle arrest or apoptosis through its transcriptional
activity [57]. Activation of p53 induces expression of cell cycle regulators such as p21WAF1 which is
considered as an important regulator of cell cycle [58]. Moreover, activation of p53 leads to activation
of the intrinsic pathway by increasing the expression of many pro-apoptotic proteins such as Bax
and Bid. After reception of the death signal, Bax; a Bcl-2 family protein, induces cell death through
disruption of mitochondrial permeability and subsequent release of cytochrome c where it engages in
a cascade of interactions that leads to the execution stage of apoptosis [59]. In this study, the obtained
results revealed that compound 9a increased the level of p53, p21 and Bax in MCF-7 cells treated with
the IC50 (2 µM) of compound 9a for 24 h compared with untreated cells used as a control (Figure 5A).
It is known that interactions between the pro- and antiapoptotic members of Bcl-2 family integrate
diverse upstream signals to determine the cellular response. Apoptosis occurs through competitive
dimerization between the two protein groups [60]. Accordingly, an increased ratio of Bax to Bcl-2 leads
to programmed cell death. Therefore, we analyzed the level of Bcl-2 protein following treatment of
MCF-7 cells with 2 µM 9a for 24 h and the obtained data portrayed that the level of Bcl-2 protein was
decreased (Figure 5B). Mouse Double Minute 2 Homolog (MDM2) and Akt are negative regulators
of p53 and the apoptotic process. Therefore, we evaluated the effect of 9a on these regulators. The
obtained data showed that 9a decreased levels of both MDM2 and Akt (Figure 5B). Cytochrome c,
a component of the mitochondrial electron transfer chain, is released into the cytosol during the
early phases of apoptosis. Therefore the accumulation of mitochondrial cytochrome c release in the
cytosol was determined by immunoblotting of the cell lysate of 9a treated cells. Data from western
blot analysis (Figure 5C) showed that treatment of MCF-7 cells with 2 µM 9a for 24 h increased the
expression of cytochrome c in cytoplasm and reduced its expression in mitochondria (Figure 5C). In
order to investigate whether compound 9a induces caspase-dependent or independent cascade we
have also studied the expression of caspase-3. Caspase 3 is activated by procaspase 3, therefore the pro
form and the active form of caspase 3 constitute a useful biomarker to confirm apoptosis. The results
of the current study revealed that compound 9a decreased the level of procaspase 3 and up-regulated
the expression of caspase-3 in MCF-7 cells treated for 24 h with 2 µM 9a (Figure 5D).To assess the
alterations of apoptosis-related death receptor protein levels in MCF-7 cells, the expression of FAS,
procaspase-8 and caspase-8 was evaluated by western blot analysis.
As shown in Figure 5E, there was no significant change in the expression of these proteins in
treated and untreated groups.
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Figure 5. Compound 9a-modulated apoptotic and survival signaling in MCF-7 cells. (A) Compound 9a
up-regulated p53, p21 and Bax. Cells were treated with 2 µM of 9a for 24 h. The MCF-7 cell lysates
were collected and the expression of p53, p21 and Bax was studied by western blot analysis using
specific antibodies in treated and non-treated control cells. β-actin was used as a loading control;
(B) Compound 9a down-regulates Bcl-2, MDM-2 and Akt levels in MCF-7 cells. Cells were treated
with 2 µM 9a for 24 h. The cell lysates were collected and the expression of Bcl-2, MDM-2 and AKT
was studied by western blot analysis using specific antibodies in treated and non-treated control cells.
β-actin was used as a loading control; (C) Total proteins in cytosol and mitochondrial fraction were
extracted and western blotting analysis was applied to determine the protein levels of cytochrome c in
treated and on-treated cells; (D) Compound 9a up-regulates the level of caspase-3 in MCF-7 Cells.
Cells were treated with 2 µM 9a for 24 h, cells were lysed and total protein was collected and subjected
to western blot analysis to determine pro-caspase and caspase-3 proteins expres ion levels in treated
and non-treated control cells. β-actin was used as a loading control; (E) The cell lysates were collected
and the expres ion levels of FAS, procaspase-8 and caspase-8 was tudied by western blotting analysis
using specific antibodies, β-actin was used as loading control.
The Effect of 9a on the Expression of Angiogenesis-Related Genes
AKT is a serine/threonine protein kinase that plays a key role in multiple cellular processes
including etabolis , proliferation, apoptosis/survival, and migration. Phosphorylation of Akt
at S473 activates Akt which is involved in the angiogenic process [61]. On the other hand, the
WNT/β-catenin signaling pathway plays an important role in carcinogenesis and tumor metastasis, in
many cancer types including breast cancer [62]. Therefore, we further investigated the possible effects
of compound 9a on the expression of phospho AKT and β-catenin. Our data clearly revealed that 9a
reduced the expression of phospho AKT and β-catenin in dose-dependent manner (Figure 6A). The
angiogenic response is induced by growth factors such as VEGF, basic fibroblast growth factor (bFGF),
platelet-derived growth factor (PDGF), and chemokines. Matrix metallopeptidases (MMPs) such as
MMP9 plays an important role in extracellular matrix remodeling, angiogenesis and metastasis and
its increased expression was observed in a metastatic mammary cancer cell line [63]. In the present
study, the data (Figure 6B) revealed that compound 9a significantly inhibited expression of VEGF and
MMP-9 in MCF-7 cells.
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Figure 6. Compound 9a downregulated metastatic-related genes. (A) Compound 9a down-regulated 
phosphoAkt and β catenin. Cells were treated with 0.5, 1 and 2 μM of 9a for 24 h. The cell lysates were 
collected and the expression of phospho Akt and β catenin was studied by western blot analysis using 
specific antibodies in treated and non-treated control cells. β-actin was used as a loading control;  
(B) Compound 9a down-regulated MMP 9 and VEGF. Cells were treated with 2 μM of 9a for 24 h. 
The cell lysates were collected and the expression of MMP 9 and VEGF was studied by western blot 
analysis using specific antibodies in treated and non-treated control cells. β-actin was used as a 
loading control. C: control (untreated cells). 
3. Experimental Section 
3.1. General Informstion 
Melting points were determined in open-glass capillaries using Stuart capillary melting point 
apparatus (Stuart Scientific Stone, Staffordshire, UK) and are uncorrected. The IR spectra (KBr) were 
recorded using a Perkin-Elmer 1430 spectrophotometer (Perkin Elmer, Beaconsfield, UK). The  
1H-NMR and 13C-NMR spectra were determined on a Mercury VX-300 MHz spectrometer (Varian, 
San Diego, CA, USA) using tetramethylsilane (TMS) as internal standard and DMSO-d6 as solvent 
(chemical shifts are given in δ ppm). Mass spectra were run on a GCMS-QP 2010 Plus (70 eV) gas 
chromatograph/mass spectrometer (Shimadzu, Kyoto, Japan). Microanalyses were performed  
at the Regional Center for Mycology and Biotechnology, El-Azhar University (Cairo, Egypt). The 
microanalyses results were within ±0.4% of the calculated values. Monitoring of reactions and 
checking the purity of the compounds was done by thin layer chromatography (TLC) on silica  
gel-precoated aluminium sheets (Type 60 GF254; Merck, Munich, Germany) and the spots were 
detected by exposure to UV lamp at λ 254 nm for a few seconds. 
3.2. Chemistry 
3.2.1. 4,6-bis(3,4-Dimethoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (3) 
A mixture of 3,4-dimethoxybenzaldehyde 1 (1.66 g, 0.01 mol), 3,4-dimethoxyacetophenone 2 (1.8 g, 
0.01 mol), ethyl cyanoacetate (1.13 g, 0.01 mol) and anhydrous ammonium acetate (7.71 g, 0.1 mol) in 
ethanol (50 mL) was stirred and heated under reflux for 12 h. The reaction mixture was allowed to 
cool and the obtained precipitate was filtered, washed with cold ethanol, dried and crystallized from 
dimethyl formamide/ethanol (2:1). Yield: 70%, m.p.: 180–182 °C. IR (ν cm−1): 3455 (NH), 2216  
(CN), 1653 (C=O), 1267, 1021 (C-O-C). 1H-NMR (ppm): 3.84 (s, 6H, 2 OCH3), 3.87 (s, 6H, 2 OCH3), 6.83  
(s, 1H, pyridine C5-H), 7.09 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.14 (d, J = 9.0 Hz, 1H, 
dimethoxyphenyl C5-H), 7.33 (s, 1H, dimethoxyphenyl C2-H), 7.35 (s, 1H, dimethoxyphenyl C2-H), 
7.47 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C6-H), 7.53 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C6-H), 12.25 
(s, 1H, NH). Anal. Calcd (%) for C22H20N2O5 (392.4): C, 67.34; H, 5.14; N, 7.14. Found: C, 67.09; H, 5.11; 
N, 6.99. 
3.2.2. General Procedure for the Synthesis of Compounds 4a–d 
To a solution of the cyanopyridone 3 (0.39 g, 0.001 mol) in dry acetone (5 mL) containing anhydrous 
potassium carbonate (0.14 g, 0.001 mol), the appropriate alkyl halide or chloroacetone (0.001 mol) 
was added dropwise. The reaction mixture was stirred and heated under reflux for 2 h then allowed 
Figure 6. Compound 9a downregulated metastatic-related genes. (A) Compound 9a down-regulated
phosphoAkt and β catenin. Cells were treated with 0.5, 1 and 2 µM of 9a for 24 h. The cell lysates
were collected and the expression of phospho Akt and β catenin was studied by western blot analysis
using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control;
(B) Compound 9a down-regulated MMP 9 and VEGF. Cells were treated with 2 µM of 9a for 24 h. The
cell lysates were collected and the expression of MMP 9 and VEGF was studied by western blot analysis
using specific antibodies in treated and non-treated control cells. β-actin was used as a loading control.
C: control (untreated cells).
3. Experimental Section
3.1. General Informstion
Melting points were determined in open-glass capillaries using Stuart capillary melting point
apparatus (Stuart Scientific Stone, Staffordshire, UK) and are uncorrected. The IR spectra (KBr) were
recorded using a Perkin-Elmer 1430 spectrophotometer (Perkin Elmer, Beaconsfield, UK). The 1H-NMR
and 13C-NMR spectra were determined on a Mercury VX-300 MHz spectrometer (Varian, San Diego,
CA, USA) using tetramethylsilane (TMS) as internal standard and DMSO-d6 as solvent (chemical shifts
are given in δ ppm). Mass spectra were run on a GCMS-QP 2010 Plus (70 eV) gas chromatograph/mass
spectrometer (Shi adzu, Kyoto, Japan). Microanalyses were performed at the Regional Center
for Mycology and Biotechnology, El-Azhar University (Cairo, Egypt). The microanalyses results
were within ˘0.4% of the calculated values. Monitoring of reactions and checking the purity of the
compounds was done by thin layer chromatography (TLC) on silica gel-precoated aluminium sheets
(Type 60 GF254; Merck, Munich, Germany) and the spots were detected by exposure to UV lamp at
λ 254 nm for a few seconds.
3.2 Chemistry
3.2.1. 4,6-bis(3,4-Dimethoxyphenyl)-2-oxo-1,2-dihydropyridine-3-carbonitrile (3)
A mixture of 3,4-dimethoxybenzaldehyde 1 (1.66 g, 0.01 mol), 3,4-dimethoxyacetophenone 2 (1.8 g,
0.01 mol), ethyl cyanoacetate (1.13 g, 0.01 ol) and anhydrous a oniu acetate (7.71 g, 0.1 mol)
in ethanol (50 mL) was stirred and heated under reflux for 12 h. The reaction mixture was allowed
to cool and the obtained precipitate was filtered, washed with cold ethanol, dried and crystallized
from dimethyl for amide/ethanol (2:1). Yield: 70%, m.p.: 180–182 ˝C. IR (ν cm´1): 3455 (NH), 2216
(CN), 1653 (C=O), 1267, 1021 ( - - ). 1 - (pp ): 3.84 (s, 6H, 2 OCH3), 3.87 (s, 6H, 2 OCH3),
6.83 (s, 1H, pyridine C5-H), 7.09 (d, J = 8.7 Hz, 1H, di ethoxyphenyl - ), 7.14 (d, J = 9.0 Hz, 1H,
dimethoxyphenyl C5-H), 7.33 (s, 1H, dimethoxyphenyl C2-H), 7.35 (s, 1H, dimethoxyphenyl C2-H),
7.47 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C6-H), 7.53 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C6-H), 12.25
(s, 1H, NH). Anal. Calcd ( ) for 0N2O5 (392.4): C, 67.34; H, 5.14; N, 7.14. Found: C, 67.09; H,
5.11; N, 6.99.
3.2.2. General Procedure for the Synthesis of Compounds 4a–d
To a solution of the cyanopyridone 3 (0.39 g, 0.001 mol) in dry acetone (5 mL) containing anhydrous
potassium carbonate (0.14 g, 0.001 mol), the appropriate alkyl halide or chloroacetone (0.001 mol) was
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added dropwise. The reaction mixture was stirred and heated under reflux for 2 h then allowed to
attain room temperature. It was then poured onto crushed ice and the separated solid product was
filtered, washed with water, dried and crystallized from the proper solvent.
2-Methoxy-4,6-bis(3,4-dimethoxyphenyl)pyridine-3-carbonitrile (4a). Yield: 72%, m.p.: 155–156 ˝C (ethanol).
IR (ν cm´1): 2213 (CN), 1586 (C=N), 1263, 1223, 1024 (C-O-C). 1H-NMR (ppm): 3.71 (s, 3H, OCH3),
3.73 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.98 (d, J = 8.7 Hz,
1H, dimethoxyphenyl C5-H), 7.07 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.31–7.37 (m, 2H,
dimethoxyphenyl C2,6-H), 7.75 (s, 1H, pyridine C5-H), 7.78 (d, J = 2.1 Hz, 1H, dimethoxyphenyl C2-H),
7.79 (d, J =8.4, 2.1 Hz, 1H, dimethoxyphenyl C6-H). 13C-NMR (DMSO-d6, ppm): 55.36, 55.42, 55.56,
55.60, 55.64, 90.46, 110.12, 111.74, 111.79, 111.89, 113.13, 115.69, 120.64, 121.56, 127.83, 128.91, 148.59,
148.81, 150.23, 151.12, 156.10, 156.69, 163.08. Anal. Calcd (%) for C23H22N2O5 (406.43): C, 67.97; H, 5.46;
N, 6.89. Found: C, 68.13; H, 5.44; N, 7.03.
2-Ethoxy-4,6-bis(3,4-dimethoxyphenyl)pyridine-3-carbonitrile (4b). Yield: 73%, m.p.: 152–153 ˝C (ethanol).
IR (ν, cm´1): 2220 (CN), 1582 (C=N), 1265, 1226, 1027 (C-O-C). 1H-NMR (ppm): 1.44 (t, J = 6.9 Hz, 3H,
CH3), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 4.62 (q, J = 6.9 Hz,
2H, OCH2), 7.10 (d, J = 8.9 Hz, 1H, dimethoxyphenyl C5-H), 7.15 (d, J = 8.3 Hz, 1H, dimethoxyphenyl
C5-H), 7.29–7.35 (m, 2H, dimethoxyphenyl C2,6-H), 7.75 (s, 1H, pyridine C5-H), 7.78 (d, J = 2.1 Hz, 1H,
dimethoxyphenyl C2-H), 7.80 (dd, J = 8.3, 2.1 Hz, 1H, dimethoxyphenyl C6-H). 13C-NMR (ppm): 14.8,
55.45, 55.58, 55.59, 55.66, 63.88, 90.49, 110.14, 111.73, 111.77, 111.94, 113.18, 115.72, 120.73, 121.64, 127.94,
129.01, 148.66, 148.84, 150.19, 151.18, 156.21, 156.82, 163.22. EI-MS m/z (%): 420.17 (M+) (77 %), 111
(100%). Anal. Calcd (%) for C24H24N2O5 (420.46): C, 68.56; H, 5.75; N, 6.66. Found: C, 68.72; H, 5.78;
N, 6.79.
4,6-bis(3,4-Dimethoxyphenyl)-2-propoxypyridine-3-carbonitrile (4c). Yield: 64%, m.p.: 156–158 ˝C
(dimethylformamide/ethanol 2:1). IR (ν cm´1): 2214 (CN), 1583 (C=N), 1264, 1228, 1026 (C-O-C).
1H-NMR (ppm): 0.93 (t, J = 6.9 Hz, 3H, CH2CH3), 1.65–1.70 (m, 2H, CH2CH3), 3.77 (s, 3H, OCH3), 3.80
(s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 4.83 (t, J = 6.9 Hz, 2H, OCH2), 6.96 (d, J = 8.3 Hz,
1H, dimethoxyphenyl C5-H), 7.08 (d, J = 8.5 Hz, 1H, dimethoxyphenyl C5-H), 7.22 (dd, J = 8.3, 1.8 Hz,
1H, dimethoxyphenyl C6-H), 7.26 (d, J = 1.8 Hz, 1H, dimethoxyphenyl C2-H), 7.67 (s, 1H, pyridine
C5-H), 7.70 (d, J = 1.8 Hz, 1H, dimethoxyphenyl C2-H), 7.77 (dd, J = 8.5, 1.8 Hz, 1H, dimethoxyphenyl
C6-H). 13C-NMR (ppm): 11.76, 23.84, 55.49, 55.55, 55.61, 55.68, 65.23, 90.56, 110.22, 111.65, 111.82,
112.12, 113.33, 115.68, 120.80, 121.66, 128.01, 129.14, 148.73, 148.69, 150.26, 151.34, 156.27, 156.94, 163.25.
Anal. Calcd (%) for C25H26N2O5 (434.48): C, 69.11; H, 6.03; N, 6.45. Found: C, 68.77; H, 5.73; N, 6.59.
4,6-bis(3,4-Dimethoxyphenyl)-2-(2-oxopropoxy)pyridine-3-carbonitrile (4d). Yield: 75%, m.p.: 110–112 ˝C
(ethanol). IR (ν cm´1): 2214 (CN), 1731 (C=O), 1593 (C=N), 1262, 1023 (C-O-C). 1H-NMR (ppm): 2.23 (s,
3H, COCH3), 3.72 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 5.25 (s, 2H,
OCH2), 7.08 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.17 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H),
7.33 (dd, J = 8.7 Hz, 2.1 Hz, 1H, dimethoxyphenyl C6-H), 7.37 (d, J = 2.1 Hz, 1H, dimethoxyphenyl
C2-H), 7.66 (s, 1H, pyridine C5-H), 7.77 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C6-H), 7.78 (d, J = 2.1 Hz,
1H, dimethoxyphenyl C2-H). 13C-NMR (ppm):25.73, 55.47, 55.54, 55.57, 55.62, 70.62, 90.42, 110.07,
111.63, 111.71, 111.92, 113.05, 115.66, 120.75, 121.50, 127.87, 128.84, 148.54, 148.76, 150.29, 151.06, 156.07,
156.64, 162.96, 203.32. Anal. Calcd (%) for C25H24N2O6 (448.47): C, 66.95; H, 5.39; N, 6.25. Found: C,
67.15; H, 5.44; N, 6.21.
3.2.3. Ethyl 2-(3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetate (5)
A mixture of 3 (3.92 g, 0.01 mol), ethyl bromoacetate (1.67 g, 0.01 mol) and anhydrous potassium
carbonate (5.53 g, 0.04 mol) in dry acetone (30 mL) was heated under reflux for 20 h. After cooling,
water was added and the reaction mixture was left in a refrigerator for an overnight. The separated
solid product was filtered, washed with water, dried and recrystallized from ethanol. Yield: 72%, m.p.:
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130–132 ˝C. IR (ν cm´1): 2220 (CN), 1760 (C=O), 1595 (C=N), 1258, 1231, 1067, 1028 (C-O-C). 1H-NMR
(ppm): 1.15 (t, J = 7.1 Hz, 3H, CH2CH3), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 6H, 2OCH3),
4.17 (q, J = 7.1 Hz, 2H, CH2CH3), 5.14 (s, 2H, OCH2), 7.08 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H),
7.16 (d, J = 8.3 Hz, 1H, dimethoxyphenyl C5-H), 7.32–7.38 (m, 2H, dimethoxyphenyl C2,6-H), 7.73 (d,
J = 1.9 Hz, 1H, dimethoxyphenyl C2-H), 7.81 (dd, J = 8.3, 1.9 Hz, 1H, C6-H), 7.84 (s, 1H, pyridine C5-H).
13C-NMR (ppm):13.88, 55.51, 55.63, 55.59, 55.63, 60.81, 63.61, 90.45, 110.34, 111.57, 111.72, 111.99, 113.12,
115.52, 120.79, 121.53, 127.82, 128.66, 148.58, 148.78, 150.35, 151.22, 156.21, 156.47, 162.82, 168.51. Anal.
Calcd (%) for C26H26N2O7 (478.49): C, 65.26; H, 5.48; N, 5.85. Found: C, 65.38; H, 5.53; N, 5.97.
3.2.4. 2-{[3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl]oxy}acetohydrazide (6)
To a suspension of 5 (4.8 g, 0.01 mol) in absolute ethanol (50 mL), hydrazine hydrate 98% (3.2 g,
0.1 mol) was added. The reaction mixture was heated under reflux for 8 h then allowed to cool to room
temperature. The obtained product was filtered, washed with ethanol, dried and recrystallized from
ethyl alcohol/dimethylformamide mixture (3:1). Yield: 68%, m.p.: 216–218˝C. IR (ν cm´1): 3437, 3303
(NH), 2209 (CN), 1690 (C=O), 1645 (C=N), 1268, 1019 (C-O-C). 1H-NMR (ppm): 3.83 (s, 3H, OCH3),
3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 4.27 (s, 2H, NH2, D2O exchangeable), 4.97 (s,
2H, OCH2), 7.07 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.17 (d, J = 8.8 Hz, 1H, dimethoxy-phenyl
C5-H), 7.29–7.35 (m, 2H, dimethoxyphenyl C2,6-H), 7.75 (d, J = 2.0 Hz, 1H, dimethoxyphenyl C2-H),
7.80 (s, 1H, pyridine C5-H), 7.82 (dd, J = 8.8, 2.0 Hz, 1H, dimethoxyphenyl C6-H), 9.36 (s, 1H, NH).
13C-NMR (ppm): 55.54, 55.66, 55.56, 55.67, 63.65, 90.44, 110.38, 111.63, 111.70, 112.22, 113.16, 115.56,
120.77, 121.55, 127.88, 128.74, 148.68, 148.82, 150.42, 151.26, 156.18, 156.51, 162.85, 168.46. Anal. Calcd
(%) for C24H24N4O6 (464.47): C, 62.06; H, 5.21; N, 12.06. Found: C, 62.29; H, 5.28; N, 12.12.
3.2.5. General Procedure for the Synthesis of Compounds 7a–d
To a well stirred cold suspension of fine powdered potassium hydroxide (0.11 g, 0.002 mol) in
dimethylformamide (4 mL) the acid hydrazide 6 (0.46 g, 0.001 mol) was added followed by carbon
disulphide (0.076 g, 0.001 mol). The reaction mixture was stirred at room temperature overnight
then the appropriate alkyl halide (0.001 mol) was added and the mixture was further stirred at room
temperature for 12 h. The reaction mixture was concentrated under reduced pressure then poured into
ice-cold water and the obtained precipitate was filtered, washed with water, dried and crystallized
from ethanol.
Methyl 2-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]hydrazinecarbodithioate (7a). Yield:
63%, m.p.:151–153 ˝C. IR (ν cm´1): 3433 (NH), 2214 (CN), 1675 (C=O), 1589 (C=N), 1516, 1314, 1145, 977
(NCS), 1261, 1023 (C-O-C). 1H-NMR (ppm): 2.69 (s, 3H, SCH3), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3),
3.86 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 5.78 (s, 2H, OCH2), 7.07 (d, J = 8.7 Hz, 1H, dimethoxyphenyl
C5-H), 7.16 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.32–7.38 (m, 2H, dimethoxyphenyl C2,6-H),
7.80 (d, J = 1.8 Hz, 1H, dimethoxyphenyl C2-H), 7.84–7.88 (m, 2H, dimethoxyphenyl C6-H and pyridine
C5-H), 10.40 (s, 1H, NH), 10.59 (s, 1H, NH). 13C-NMR (ppm):16.28, 55.67, 58.14, 64.21, 91.25, 110.37,
111.59, 111.77, 112.22, 113.62, 115.39, 120.84, 121.56, 127.85, 128.72, 148.63, 148.90, 150.42, 151.31, 156.29,
156.74, 162.44, 164.60, 172.26. EI-MS m/z (%): 554 (M+) (19.5 %), 94 (100%). Anal. Calcd (%) for
C26H26N4O6S2 (554.64): C, 56.30; H, 4.72; N, 10.10. Found: 56.38; H, 4.75; N, 10.21.
Ethyl 2-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]hydrazinecarbodithioate (7b). Yield:
64%, m.p.: 144–146 ˝C. IR (ν cm´1): 3437 (NH), 2214 (CN), 1672 (C=O), 1591 (C=N), 1516, 1307, 1144,
979 (NCS), 1261, 1025 (C-O-C). 1H-NMR (ppm): 1.28 (t, J = 7.1 Hz, 3H, CH3), 3.18 (q, J = 7.1 Hz, 2H,
SCH2), 3.76 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.83 (s, 2H,
OCH2), 7.07 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.1 Hz, 1H, dimethoxyphenyl
C5-H), 7.28-7.32 (m, 2H, dimethoxyphenyl C2,6-H), 7.73–7.86 (m, 3H, dimethoxyphenyl C2,6-H and
pyridine C5-H), 10.42 (s, 1H, NH), 10.63 (s, 1H, NH). 13C-NMR (ppm): 14.54, 26.61, 55.64, 58.07, 63.98,
90.78, 110.49, 111.56, 111.74, 112.14, 113.58, 115.37, 120.87, 121.54, 127.80, 128.68, 148.61, 148.89, 150.40,
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151.24, 156.33, 156.70, 162.41, 163.78, 171.98. Anal. Calcd (%) for C27H28N4O6S2 (568.66): C, 57.03; H,
4.96; N, 9.85. Found: C, 57.17; H, 4.92; N, 9.91.
2-Morpholinoethyl-2-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]hydrazinecarbo-dithioate
(7c). Yield: 66 %, m.p.: 158–160 ˝C. IR (ν, cm´1): 3435 (NH), 2217 (CN), 1656 (C=O), 1586 (C=N), 1516,
1322, 1138, 921 (NCS), 1262, 1022 (C-O-C). 1H-NMR (ppm): 2.60–2.64 (m, 4H, morpholine C3,5-H2),
2.74 (t, J = 6.9 Hz, 2H, SCH2), 2.94 (t, J = 6.9 Hz, 2H, NCH2), 3.59–3.64 (m, 4H, morpholine C2,6-H2),
3.78 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.72 (s, 2H, OCH2), 7.06
(d, J = 8.1 Hz, 1H, dimethoxyphenyl C5-H), 7.14 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.28–7.33
(m, 2H, dimethoxyphenyl C2,6-H), 7.75–7.81 (m, 3H, dimethoxyphenyl C2,6-H and pyridine C5-H),
10.49 (s, 1H, NH), 10.67 (s, 1H, NH). 13C-NMR (ppm): 32.83, 52.10, 55.65, 55.67, 56.13, 58.07, 64.69,
90.73, 110.41, 111.57, 111.72, 113.11, 113.58, 115.36, 120.86, 121.55, 127.80, 128.67, 148.59, 148.89, 150.38,
151.21, 156.37, 156.72, 162.35, 164.30, 172.0. Anal. Calcd (%) for C31H35N5O7S2 (653.77): C, 56.95; H,
5.40; N, 10.71. Found: 56.61; H, 5.18; N, 11.04.
2-(Piperidin-1-yl)-ethyl-2-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]hydrazinecarbo-
dithioate (7d). Yield: 66 %, m.p.: 160–162 ˝C. IR (ν, cm´1): 3434 (NH), 2218 (CN), 1645 (C=O), 1587
(C=N), 1516, 1322, 1134, 921 (NCS), 1262, 1022 (C-O-C). 1H-NMR (ppm): 1.44–1.48 (m, 2H, piperidine
C4-H2), 1.60–1.64 (m, 4H, piperidine C3,5-H2), 2.83–3.07 (m, 8H, piperidine C2,6-H, SCH2 and NCH2),
3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 5.64 (s, 2H, OCH2), 7.08
(d, J = 8.1 Hz, 1H, dimethoxyphenyl C5-H), 7.20 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.33–7.38
(m, 2H, dimethoxyphenyl C2,6-H), 7.71–7.85 (m, 3H, dimethoxyphenyl C2,6-H and pyridine C5-H),
10.51 (s, 1H, NH), 10.69 (s, 1H, NH). 13C-NMR (ppm): 23.76, 33.14, 52.26, 53.82, 55.65, 55.67, 63.99,
91.33, 110.42, 111.55, 111.76, 113.14, 113.59, 115.54, 120.88, 121.61, 127.84, 128.69, 148.55, 148.93, 150.27,
151.33, 156.44, 156.81, 162.46, 164.42, 174.20. Anal. Calcd (%) for C32H37N5O6S2 (651.8): C, 58.97; H,
5.72; N, 10.74. Found: 58.99; H, 5.83; N, 10.92.
3.2.6. General Procedure for the Synthesis of Compounds 8a–c
A mixture of 6 (0.464 g, 0.001 mol) and the appropriate aldehyde (0.001 mol) in absolute ethanol
(20 mL) containing 2 drops of glacial acetic acid was heated under reflux for 8 h. The reaction mixture
was allowed to attain room temperature and the separated solid product was filtered, washed with
ethanol, dried and recrystallized from dimethylformamide.
2-[3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl]oxy-N'-(4-methoxybenzylidene)acetohydrazide (8a).
Yield: 84%, m.p.: 163–164 ˝C. IR (ν, cm´1): 3189 (NH), 2224 (CN), 1673 (C=O), 1601 (C=N), 1257, 1026
(C-O-C). 1H-NMR (ppm):3.64 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 3.86 (s, 3H, OCH3),
3.88 (s, 3H, OCH3), 5.09 (s, 2H, OCH2, cis conformer), 5.60 (s, 2H, OCH2, trans conformer), 6.95–7.03
(m, 3H, dimethoxyphenyl C5-H and methoxyphenyl C3,5-H), 7.18 (d, J = 8.4 Hz, 1H, dimethoxyphenyl
C5-H), 7.33–7.37 (m, 2H, dimethoxyphenyl C2,6-H), 7.62–7.72 (m, 4H, dimethoxyphenyl C2,6-H and
methoxyphenyl C2,6-H), 7.79 (s, 1H, pyridine C5-H), 8.0 (s, 1H, N=CH, cis conformer), 8.22 (s, 1H,
N=CH, trans conformer), 11.58 (s, 1H, NH, cis conformer), 11.62 (s, 1H, NH, trans conformer). 13C-NMR
(ppm): 55.22, 55.51, 55.64, 70.15, 90.45, 109.94, 111.50, 111.76, 112.30, 113.59, 114.29, 115.66, 120.73,
121.48, 127.40, 128.10, 128.33, 128.43, 142.50, 148.55, 148.85, 150.38, 151.19, 155.80, 156.04, 160.75, 163.50,
164.34. Anal. Calcd (%) for C32H30N4O7 (582.6): C, 65.97; H, 5.19; N, 9.62. Found: C, 66.12; H, 5.43;
N, 9.91.
2-[3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl]oxy-N'-(3,4-dimethoxybenzylidene)acetohydrazide (8b).
Yield: 82%, m.p.:190–192 ˝C. IR (ν, cm´1): 3200, 3133 (NH), 2210 (CN), 1696 (C=O), 1581 (C=N), 1264,
1023 (C-O-C). 1H-NMR (DMSO-d6, ppm): 3.66 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.80 (s, 3H, OCH3),
3.82 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 5.11 (s, 2H, OCH2, cis conformer), 5.62 (s,
2H, OCH2, trans conformer), 6.96 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.16–7.20 (m, 2H, two
dimethoxyphenyl C5-H), 7.33–7.79 (m, 6H, three dimethoxyphenyl C2,6-H), 7.98 (s, 1H, pyridine C5-H),
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8.0 (s, 1H, N=CH, cis conformer), 8.18 (s, 1H, N=CH, trans conformer), 11.68 (s, 1H, NH, cis conformer),
11.72 (s, 1H, NH, trans conformer). 13C-NMR (ppm): 55.20, 55.45, 55.56, 55.62, 70.26, 90.26, 110.10,
110.85, 111.53, 111.77, 111.96, 113.20, 113.83, 115.74, 120.98, 121.82, 123.50, 127.74, 128.44, 129.12, 144.36,
148.58, 148.80, 149.05, 149.85, 150.32, 151.18, 155.93, 156.34, 163.88, 164.42.EI-MS m/z (%): 612 (M+)
(14.34%), 69.0 (100%). Anal. Calcd (%) for C33H32N4O8 (612.63): C, 64.70; H, 5.26; N, 9.15. Found: C,
64.82; H, 5.22; N, 9.23.
2-[3-Cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl]oxy-N'-(3,4,5-trimethoxybenzylidene)acetohydrazide
(8c). Yield: 79 %, m.p.: 232–234 ˝C. IR (ν, cm´1): 3204 (NH), 2217 (CN), 1670 (C=O), 1586 (C=N),
1263, 1022 (C-O-C). 1H-NMR (ppm): 3.67 (s, 3H, OCH3), 3.70 (s, 3H, OCH3), 3.78 (s, 3H, OCH3),
3.81 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 5.10 (s, 2H, OCH2,
cis conformer), 5.63 (s, 2H, OCH2, trans conformer), 6.98 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H),
7.06 (s, 1H, trimethoxyphenyl-H), 7.18 (d, J = 8.1 Hz, 1H, dimethoxyphenyl C5-H), 7.32–7.37 (m, 3H,
dimethoxyphenyl-C2,6-H and trimethoxyphenyl-H), 7.71 (d, J = 1.8 Hz, 1H, dimethoxyphenyl C2-H),
7.78–7.81 (m, 2H, pyridine C5-H and dimethoxyphenyl C6-H), 7.96 (s, 1H, N=CH, cis conformer), 8.19
(s, 1H, N=CH, trans conformer), 11.76 (s, 1H, N=H, cis conformer), 11.80 (s, 1H, NH, trans conformer).
13C-NMR (ppm): 55.53, 55.68, 56.33, 56.46, 60.45, 70.37, 90.48, 104.60, 110.08, 110.79, 111.62, 111.88,
112.47, 115.58, 120.98, 121.82, 127.78, 128.52, 130.37, 139.64, 144.64, 148.58, 149.05, 149.85, 150.32, 153.76,
155.88, 157.11, 164.29, 165.12. Anal. Calcd (%) for C34H34N4O9 (642.66): C, 63.54; H, 5.33; N, 8.72.
Found: C, 63.59; H, 5.36; N, 8.81.
3.2.7. General Procedure for the Synthesis of Compounds 9a,b and 10a,b
To a suspension of 6 (0.464 g, 0.001 mol) in dry pyridine (5 mL), the appropriate aroyl chloride
or sulfonyl chloride (0.001 mol) was slowly added at 0 ˝C. The reaction mixture was stirred at room
temperature overnight then poured into ice-cold water. The obtained precipitate was filtered, washed
with water, dried and crystallized from dimethylformamide/ethanol mixture (3:1).
N'-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]benzohydrazide (9a). Yield: 67 %, m.p.:
222–224 ˝C. IR (ν, cm´1): 3416, 3168 (NH), 2216 (CN), 1680 (C=O), 1605 (C=N), 1261, 1025 (C-O-C).
1H-NMR (ppm): 3.84 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 5.19 (s,
2H, OCH2), 7.08 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.18 (d, J = 9.0 Hz, 1H, dimethoxyphenyl
C5-H), 7.33–7.76 (m, 2H, dimethoxyphenyl C2,6-H), 7.46–7.57 (m, 3H, phenyl C3,4,5-H), 7.83–7.92 (m,
5H, phenyl C2,6-H, dimethoxyphenyl C2,6-H and pyridine C5-H), 10.41 (s, 1H, NH), 10.50 (s, 1H,
NH). 13C-NMR (ppm): 55.56, 55.59, 55.64, 55.67, 64.68, 90.23, 110.27, 111.65, 111.72, 112.31, 113.16,
115.66, 120.73, 121.46, 127.67, 127.82, 128.43, 128.79, 132.45, 133.89, 148.75, 148.69, 150.38, 151.42, 156.18,
156.51, 162.85, 166.12, 168.46. EI-MS m/z (%): 568.0 (M+) (16.36 %), 153.90 (100%). Anal. Calcd (%) for
C31H28N4O7 (568.58): C, 65.48; H, 4.96; N, 9.85. Found: C, 65.56; H, 4.98; N, 9.97.
N'-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]-4-methoxybenzo hydrazide (9b). Yield:
69%, m.p.: 170–172 ˝C. IR (ν, cm´1): 3440, 3173 (NH), 2218 (CN), 1667 (C=O), 1604 (C=N), 1261,
1023 (C-O-C). 1H-NMR (ppm): 3.81 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s,
3H, OCH3), 3.88 (s, 3H, OCH3),5.16 (s, 2H, OCH2), 7.01 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H),
7.08 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C5-H), 7.17 (d, J = 8.7 , 2.1 Hz, 2H, methoxyphenyl C3,5-H),
7.32–7.35 (m 2H, dimethoxyphenyl C2,6-H), 7.81–7.90 (m, 5H, dimethoxyphenyl C2,6-H, pyridine C5-H
and methoxyphenyl C2,6-H), 10.33 (s, 2H, 2NH). 13C-NMR (ppm): 55.59, 55.62, 55.64, 55.68, 55.77,
63.69, 90.17, 110.14, 111.63, 111.74, 112.13, 113.25, 114.23, 115.69, 120.74, 121.56, 125.81, 127.77, 128.43,
128.72, 148.63, 148.79, 150.44, 151.21, 156.43, 156.58, 163.12, 165.40, 165.90, 168.46. Anal. Calcd (%) for
C32H30N4O8 (598.6): C, 64.21; H, 5.05; N, 9.36. Found: C, 64.37; H, 5.03; N, 9.44.
N'-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acety]benzenesulfohydrazide (10a). Yield: 65%,
m.p.: 120–122 ˝C. IR (ν, cm´1): 3454, 3233 (NH), 1711 (C=O), 1587 (C=N), 1330, 1165 (SO2), 1261,
1021 (C-O-C). 1H-NMR (ppm): 3.83 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.90 (s,
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3H, OCH3), 4.96 (s, 2H, OCH2), 7.06 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.9 Hz,
1H, dimethoxyphenyl C5-H), 7.23–7.85 (m, 10H, two dimethoxyphenyl C2,6-H, pyridine C5-H and
phenyl-H), 10.06 (s, 1H, NH), 10.49 (s, 1H, NH). 13C-NMR (ppm): 55.48, 55.56, 55.62, 55.68, 64.66, 90.29,
110.25, 111.66, 111.74, 112.36, 113.14, 115.60, 120.69, 121.50, 127.64, 128.08, 128.47, 128.89, 132.39, 138.91,
148.68, 148.73, 150.42, 151.44, 156.22, 156.54, 162.93, 166.48. Anal. Calcd (%) for C30H28N4O8S (604.63):
C, 59.59; H, 4.67; N, 9.27. Found: C, 59.78; H, 4.60; N, 9.39.
N'-[2-(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yloxy)acetyl]-4-methoxybenzenesulfohydrazide (10b).
Yield: 65 %, m.p.: 190–192 ˝C. IR (ν, cm´1): 3446, 3238 (NH), 1708 (C=O), 1588 (C=N), 1333, 1166 (SO2),
1258, 1030 (C-O-C). 1H-NMR (ppm): 3.80 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s,
3H, OCH3), 3.89 (s, 3H, OCH3), 4.97 (s, 2H, OCH2), 7.0 (d, J = 9.0 Hz, 1H, dimethoxyphenyl C5-H),
7.09 (d, J = 8.6 Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.8 , 2.1 Hz, 2H, methoxyphenyl C3,5-H),
7.30–7.34 (m, 2H, dimethoxyphenyl C2,6-H), 7.82–7.88 (m, 5H, dimethoxyphenyl C2,6-H, pyridine C5-H
and methoxyphenyl C2,6-H), 10.10 (s, 1H, NH), 10.48 (s, 1H, NH). 13C-NMR (ppm): 55.47, 55.58, 55.62,
55.65, 55.7), 63.6), 90.2), 110.1), 111.58, 111.76, 112.16, 113.22, 114.27, 115.73, 120.77, 121.63, 127.77,
128.43, 128.72, 130.21, 148.68, 148.81, 150.39, 151.26, 156.38, 156.62, 163.14, 165.44, 166.76. Anal. Calcd
(%) for C31H30N4O9S (634.66): C, 58.67; H, 4.76; N, 8.83. Found: C, 58.78; H, 4.60; N, 9.19.
3.2.8. General Procedure for the Synthesis of Compounds 11 and 12
A mixture of 6 (0.464 g, 0.001 mol) and acetylacetone or ethyl acetoacetate (0.001 mol) in absolute
ethanol/glacial acetic acid mixture (2:1) (15 mL) was heated under reflux for 8 h then allowed to cool
to room temperature. The separated solid product was filtered, thoroughly washed with cold ethanol,
dried and recrystallized from dimethylformamide/water mixture (4:1).
4,6-Bis(3,4-dimethoxyphenyl)-2-(2-(3,5-dimethyl-1H-pyrazol-1-yl)-2-oxoethoxy)pyridine-3-carbonitrile (11).
Yield: 67%, m.p.: 161–163 ˝C. IR (ν, cm´1): 2215 (CN), 1705 (C=O), 1591 (C=N), 1255, 1022 (C-O-C).
1H-NMR (ppm):2.19 (s, 3H, CH3), 2.38 (s, 3H, CH3), 3.74 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.78
(s, 3H, OCH3), 3.80 (s, 3H, OCH3), 5.15 (s, 2H, OCH2), 6.21 (s, 1H, pyrazole C4-H), 7.10 (d, J = 8.6
Hz, 1H, dimethoxyphenyl C5-H), 7.16 (d, J = 8.3 Hz, 1H, dimethoxyphenyl C5-H), 7.33-7.38 (m, 2H,
dimethoxyphenyl C2,6-H), 7.73 (d, J = 2.2 Hz, 1H, dimethoxyphenyl C2-H), 7.79 (dd, J = 8.3, 2.2 Hz,
1H, dimethoxyphenyl C6-H), 7.85 (s, 1H, pyridine C5-H). 13C-NMR (ppm):11.23, 12.54, 55.49, 55.64,
55.68, 55.71, 63.72, 90.28, 96.36, 110.41, 111.48, 111.73, 112.28, 113.36, 115.65, 120.76, 121.66, 127.79,
128.92, 142.89, 148.77, 148.85, 150.43, 151.33, 152.53, 156.28, 156.62, 162.89, 168.63. Anal. Calcd (%) for
C29H28N4O6 (528.56): C, 65.90; H, 5.34; N, 10.60. Found: C, 66.08; H, 5.38; N, 10.81.
4,6-bis(3,4-Dimethoxyphenyl)-2-(2-(3-methyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl)-2-oxoethoxy)pyridine-3-
carbonitrile (12). Yield: 65 %, m.p.: 189–190 ˝C. IR (ν, cm´1): 2216 (CN), 1708 (C=O), 1593 (C=N), 1261,
1023 (C-O-C). 1H-NMR (ppm): 2.49 (s, 3H, CH3), 3.67 (s, 2H, pyrazole C4-H2), 3.76 (s, 3H, OCH3),
3.78 (s, 3H, OCH3),3.81(s, 3H, OCH3), 3.83 (s, 3H, OCH3), 5.16 (s, 2H, OCH2), 7.10 (d, J = 8.7 Hz,
1H, dimethoxyphenyl C5-H), 7.17 (d, J = 8.3 Hz, 1H, dimethoxyphenyl C5-H), 7.33–7.38 (m, 2H,
dimethoxyphenyl C2,6-H), 7.72 (d, J = 2.2 Hz, 1H, dimethoxyphenyl C2-H), 7.80 (dd, J = 8.3, 2.2 Hz, 1H,
dimethoxyphenyl C6-H), 7.85 (s, 1H, pyridine C5-H). 13C-NMR (ppm): 14.95, 55.53, 55.65, 55.69, 55.96,
59.60, 63.68, 90.14, 110.29, 111.38, 111.77, 112.32, 113.44, 115.71, 120.77, 121.69, 127.88, 128.97, 142.98,
148.77, 148.85, 150.43, 151.33, 156.33, 156.67, 162.82, 162.88, 168.63. Anal. Calcd (%) for C28H26N4O7
(530.53): C, 63.39; H, 4.94; N, 10.56. Found: C, 63.47; H, 4.98; N, 10.73.
3.2.9. General Procedure for the Synthesis of Compounds 13a,b
A mixture of 6 (0.464 g, 0.001 mol) and methyl 2-cyano-3,3-bis(methylthio)acrylate or [bis
(methylthio)methylene]malononitrile (0.001 mol) in dry dimethylformamide (8 mL) was heated under
reflux for 5 h. The solvent was removed under vacuum and the residue was treated with ice cold water.
The formed precipitate was filtered, washed with ethanol, dried and crystallized from dioxane.
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Methyl 5-amino-1-{[(3-cyano-4,6-bis(3,4-dimethoxyphenyl)pyridin-2-yl)oxy]acetyl}-3-(methylsulfanyl)-1H-
pyrazole-4-carboxylate (13a). Yield: 64 %, m.p.: 184–186 ˝C. IR (ν cm´1): 3448, 3323 (NH2), 2221 (CN),
1739, 1675 (C=O), 1622 (C=N), 1261, 1019 (C-O-C). 1H-NMR (ppm): 2.49 (s, 3H, SCH3), 3.72 (s, 3H,
OCH3), 3.80 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 5.85 (s, 2H,
OCH2), 6.99 (d, J = 8.7 Hz, 1H, dimethoxyphenyl C5-H), 7.18 (d, J = 8.4 Hz, 1H, dimethoxyphenyl
C5-H), 7.34–7.38 (m, 2H, dimethoxyphenyl C2,6-H), 7.49 (s, 2H, NH2, D2O exchangeable), 7.56 (s, 1H,
dimethoxyphenyl C2-H), 7.71 (d, J = 8.4 Hz, 1H, dimethoxyphenyl C6-H), 7.84 (s, 1H, pyridine C5-H).
13C-NMR (ppm): 13.15, 51.28, 55.49, 55.64, 55.68, 55.71, 63.72, 90.28, 96.36, 110.41, 111.48, 111.73, 112.28,
113.36, 115.65, 120.76, 121.66, 127.79, 128.92, 142.89, 148.77, 148.85, 150.43, 151.33, 152.53, 156.28, 156.62,
162.89, 168.63. EI-MS m/z: 619.0 (M+) (5.14%), 64.0 (100%). Anal. Calcd (%) for C30H29N5O8S (619.64):
C, 58.15; H, 4.72; N, 11.30. Found: C, 58.32; H, 4.48; N, 11.13.
2-{2-[5-Amino-4-cyano-3-(methylsulfanyl)-1H-pyrazol-1-yl]-2-oxoethoxy}-4,6-bis(3,4-dimethoxyphenyl)-pyridine
-3-carbonitrile (13b). Yield 59 %, m.p. 202–204 ˝C. IR (ν, cm´1): 3397, 3168 (NH), 2215 (CN), 1670
(C=O), 1618 (C=N), 1267, 1020 (C-O-C). 1H-NMR (ppm): 2.49 (s, 3H, SCH3), 3.80 (s, 3H, OCH3),
3.86 (s, 3H, OCH3), 3.87 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 5.11 (s, 2H, OCH2), 6.96 (d, J = 8.7 Hz,
1H, dimethoxyphenyl C5-H), 7.14–7.20 (m, 3H, dimethoxyphenyl C5-H and NH2), 7.28–7.36 (m, 2H,
dimethoxyphenyl C2,6-H), 7.70 (s, 1H, dimethoxyphenyl C2-H), 7.75 (s, 1H, pyridine C5-H), 7.83 (d,
J = 8.4 Hz, 1H, dimethoxyphenyl C6-H). 13C-NMR (ppm):13.26, 55.52, 55.59, 55.64, 55.76, 63.78, 90.26,
91.44, 110.41, 111.55, 111.78, 112.36, 113.39, 113.56, 115.68, 120.84, 121.73, 128.11, 128.96, 143.77, 148.78,
148.89, 150.44, 151.36, 153.59, 156.34, 156.65, 162.84, 168.63. EI-MS m/z (%): 619.0 (M+) (5.14%), 64.0
(100%). Anal. Calcd (%) for C29H26N6O6S (586.62): C, 59.38; H, 4.47; N, 14.33. Found: C, 59.69; H, 4.51;
N, 14.68.
2-((5-Mercapto-1,3,4-oxadiazol-2-yl)methoxy)-4,6-bis(3,4-dimethoxyphenyl)pyridine-3-carbonitrile (14).
A mixture of 6 (0.464 g, 0.001 mol), carbon disulfide (0.076 g, 0.001 mol) and potassium hydroxide
(0.056 g, 0.001 mol) in ethanol (20 mL) was heated under reflux for 8 h. The reaction mixture was left
to cool then poured onto crushed ice and acidified with 4N hydrochloric acid. The separated solid was
filtered, washed with water, dried and crystalized from dioxane. Yield: 62%, m.p. 180–182 ˝C. IR
(ν, cm´1): 3219 (NH), 2218 (CN), 1629 (C=N), 1262,1022(C-O-C). 1H-NMR (ppm): 3.80 (s, 3H, OCH3),
3.81 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 5.69 (s, 2H, OCH2), 7.03 (d, J = 8.9 Hz,
1H, dimethoxyphenyl C5-H), 7.12 (d, J = 8.6 Hz, 1H, dimethoxyphenyl C5-H), 7.29–7.80 (m, 4H, two
dimethoxyphenyl C2,6-H), 7.82 (s, 1H, pyridine C5-H), 12.53 (s, 1H, NH). 13C-NMR (ppm): 55.64, 55.69,
55.73, 55.76, 63.88, 90.33, 110.43, 111.54, 111.80, 112.41, 113.42, 115.70, 120.87, 121.75, 128.13, 129.11,
148.81, 148.84, 150.39, 151.45, 158.35, 156.29, 156.71, 162.88,178.30.EI-MS m/z: 507.0 (M+ /11.40%), 149
(100%). Anal. Calcd (%) for C25H22N4O6S (506.53): C, 59.28; H, 4.38; N, 11.06. Found: 59.39; H, 4.35;
N, 11.22.
3.3. Biological Evaluation Methodology
3.3.1. Cell Lines and Cell Culture
The following cell lines were used for the screening stage, obtained from the American Type
Culture Collection (ATCC, Manassas, VA, USA); SK-OV-3 (HTB-77), MCF-12A (ATCC CRL-10782),
MDA-MB-231 (ATCC HTB-26), HCT-116 (CCL-247), RKO (CRL-2577) and sub-culturing of the above
cell lines was conducted in 75 cm2 flasks. The old culture media was removed and discarded after
assessing the confluency of the cells and the cells were rinsed with 2–3 mL diluted trypsin (1ˆ)
(trypsin/EDTA solution consists of 0.025% trypsin and 0.01% EDTA in PBS), for about 5 minutes for
complete detachment. The cells were observed under the inverted microscope until the cell layer is
completely dispersed. 75 cm2 flasks were prepared and 16 mL of DMEM media for SK-OV-3, MCF-7,
MDA-MB-231, (DMEM 4500 mg glucose) and RPMI media for HCT-116 were added to each flask. The
cells were aspirated gently and added to the flasks. DMEM 4500 mg/L high glucose with 10% FBS,
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5% streptomycin and penicillin, RPMI 1640 (prepared by adding 5% heat-inactivated FCS and 2 mm
glutamine) were used. DMEM was also used for MCF-12A cells with the addition of human epidermal
growth factor 20 ng/mL, insulin 0.01 mg/mL and hydrocortisone 500 ng/mL.
3.3.2. Drug Stock Preparation
The synthesized compounds were screened for their anti-proliferative activity using 5-FU
(F6627-1G, Sigma-Aldrich, St. Louis, MO, USA) as reference compound. A concentration of 0.4%
DMSO was used in all experiment after ensuring 100% viability of the cell lines with this concentration.
A 25 mM stock concentration of all compounds was prepared for further studies and analysis.
3.3.3. Cell Viability Assay (WST-1 Assay)
Cells were trypsinized and placed in a 15 mL Falcon tube, the cells were centrifuged for 3 min at
1000 rpm. Trypsin is decanted using a sterile pipette and then the pellet is loosened by flicking the
tube few times then 5–10 mL warm DMEM or RPMI were added to the Falcon tube and the pellet
is resuspended. Cell count was done next by taking 10 µL of the suspension into the cell counting
slide and read under 10ˆ cells/mL. A cell stock of 50,000 cells/mL was prepared for the 96 wells.
Cells (100 µL) were added to each well using a sterile pipette each time to ensure consistency. The
experiment was planned ahead of time using excel sheet, 3–6 wells were reserved as blank media while
3–6 wells for vehicle (DMSO). The plate was incubated for 24 h for compound treatment step. DMEM
media was used to prepare different dilutions of the compounds. The old DMEM media was removed
from the wells using sterile pipette in the hood and the media was replaced with 100 µL media with
each compound. The plate was incubated for 24 h. After 24 h incubation, WST-1 reagent (Sigma) was
added to each well and then the plate was incubated for 1 h before measuring the absorbance using
VICTOR™ Multilabel Plate Reader (Perkin Elmer, Beaconsfield, UK). The absorbance of the colored
solution can be quantified by measuring at a certain wavelength (usually between 500–600 nm), in
this experiment the first reading was conducted at 540 nm and the second reading at 690 nm for the
reference wavelength. The percentage of cell viability was determined as the ratio of the absorbance of
the sample vs the control. Three independent experiments were performed. The IC50 of each derivative
was calculated as the concentration showing 50% cell growth inhibition during 24 h of compound
treatment. 5-Florouracil (Sigma-Aldrich, F6627-1G) was used as reference standard.
3.3.4. Morphological Examination
Morphological examination was performed as described previously; MCF-7 cells were plated on
96 well plates using 5ˆ 104 cells/well and allowed to reach 75%–85% confluence. The compounds were
added to the medium, untreated cells were used as negative control, in addition to blank cells (medium)
and vehicle which consist of (DMSO 0.4% + cells). After treatment, all the cells were incubated for 24 h
in an atmosphere containing 5% CO2. After 2 h of treatment, the morphological changes of the cells
were examined and photographs were taken using an inverted microscope at 400ˆ magnification.
3.3.5. TUNEL Assay
For in situ detection of apoptotic cells, a terminal-deoxynucleotidyl transferase meditated nick
end labeling (TUNEL) assay was performed using DeadEndTM fluorimetric tunnel system (Promega,
Madison, WI, USA). Cells were cultured on 4-chamber slides (VWR, Radnor, PA, USA) at a density
of 2 ˆ 104 cells/ chamber. After treatment with compound 9a, cells were washed with phosphate
buffer saline (PBS) and fixed by incubation in 4% paraformaldehyde (PFA) for 20 min at 4 ˝C, then
permeabilized with 0.05% Triton X-100 for 5 min at 4 ˝C. The fixed cells were then incubated with
digoxigenin-conjugated dUTP in terminal deoxynucleotide transferase recombinant (rTdT)-catalyzed
reaction and nucleotide mixture for 60 min at 37 ˝C in a humidified atmosphere and then immersed
in stop/wash buffer for 15 min at room temperature. Cells were then washed with PBS to remove
unincorporated fluorescein-12-dUTP. After washing with PBS, cells were incubated in 1 µg/mL
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2-(4-amidinophenyl)-6-indole carbamidine dihydrochloride (DAPI) and fluorescein isothiocyanate
(FITC) solution for 15 min in dark. Cells were observed with fluorescence microscopy (RT slider Spot,
Diagnostic Instruments, Inc., Sterling Heights, MI, USA) and photographed at 100ˆ magnification.
3.3.6. Enzyme Linked Immunosorbent Apoptosis Assay
Cells were seeded at a density of 2 ˆ 104/ well in a 96- well plate and incubated for 24 h. Media
were changed to media containing compound 9a (2 µM). Cells were then incubated for 24 h. An
ELISA assay was performed using Cell Death Detection ELISA PLUS kit (Roche-Applied Science,
Indianapolis, IN, USA) for the quantitative in vitro determination of cytoplasmic histone-associated
DNA fragments (mono- and oligonucleosomes) in apoptosing cells. Briefly, cells were lysed with
200-µL lysis buffer for 30 min at room temperature. The lysate was centrifuged at 200 g for 10 min.
150 µL of supernatant was collected, of which 20 µL was incubated with anti-histone biotin and
anti-DNA peroxidase at room temperature for 2 h. After washing with incubation buffer three times,
100 µL of substrate solution (2,21-azino-di(3-ethylbenzthiazolinsulphonic acid) was added to each well
and incubated for 15–20 min at room temperature. The absorbance was measured using an ELISA
reader (Spectra Max Plus) at 405 nm. The control group was cells without compounds treatment. Each
assay was done in triplicate and the standard deviation was determined.
3.3.7. Flow Cytometry
Cell Cycle Analysis
MCF-7 cells were seeded in 25 cm2 flasks until reaching the desirable confluence of 1 million
cells and media was changed to media containing compound 9a (2 µM). After 24 h incubation, the
cells were harvested by trypsinization to detach the cells without affecting the integrity of the cell
membrane. The cells were incubated with PI for 5 min at room temperature, washed twice with PBS
and fixed with ice-cold 70% ethanol while vortexing. The cells were then washed and re-suspended in
PBS with 5 g/mL RNase A (Sigma) and 50 g/mL PI (Sigma) for analysis by flow cytometry. Cell cycle
analysis was performed using FACScan Flow Cytometer (Becton Dickson, Franklin Lakes, NJ, USA)
according to the manufacturer’s protocol.
3.3.8. Western Blot
Total protein was extracted from treated and untreated cells using lysis buffer (10 mM Tris-HCl
(pH 7.5), 1 mM EDTA, 1% Triton X-100, 150 mM NaCl, 1 mM dithiothretol, 10% glycerol, 0.2 mM
phenylmethysulphonyl fluoride and protease inhibitors) for 30–50 min on ice. The extracts were
centrifuged at 13,000ˆ g for 15 min at 4 ˝C to remove cell debris. Folin Lowry (Pierce, Grand Island,
NY, USA) protein assay was used to figure the protein concentration in the cell lysates. Proteins
were resolved by electrophoresis on 8%–10% sodium dodecyl sulphate-polycrylamide gel loading
equal amount of proteins per lane. The resolved proteins were transferred onto polyvinylidene
difluoride (PVDF) membrane and then probed with primary antibody against the protein of interest
prepared in 5% milk/PBS-T. The membrane was washed using phosphate buffer saline with Tween
20 (PBS-T) and then appropriate secondary antibody conjugated to horseradish peroxidase (HRP)
was used for visualization of the bands using ECL chemiluminescence kit (GE, Fairfield, CT, USA).
Anti-p27, anti-CDK2, anti-CDK4, anti-(p21), anti-(p53), anti-Bax, anti-Akt, anti-Bcl-2, anti-MDM2,
anti-cytochrome C, anti-caspase-8, anti-procaspase-8, anti-FAS, anti-VEGF, anti-MMP-9, anti-β-catenin
were purchased from SantaCruz (Dallas, TX, USA). Pixel density of the proteins studied was calculated
using Image J, version 1.41o, NIH (Bethesda, MD, USA). The values obtained were first normalized to
loading control β-actin and the fold change was measured by normalizing to that of the control (0 h)
value. At least two independent experiments were performed.
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3.3.9. Statistical Analysis
The quantitative ratios of different groups were compared using Student’s t-test. Probability
values of p < 0.05 were regarded as statistically significant. All statistical tests were two sided.
4. Conclusions
In the present study, new 3-cyano-4,6-bis (3,4-dimethoxyphenyl)-2-substituted pyridines were
synthesized and investigated for their cytotoxicity on five cancer cell lines. The results demonstrated
that the benzohydrazide derivative 9a reduced viability and induced apoptosis in MCF 7 breast cancer
cells at an IC50 value of 2 µM and was less cytotoxic to normal breast epithelial cells (MCF-12a) than
MCF 7 cells. The results of apoptosis assays and cell cycle analysis demonstrated that compound 9a
obviously inhibits the proliferation of MCF-7 cancer cells by inducing apoptosis and arresting the cell
cycle at G1 phase via inhibition of CDK2 and CDK4. In addition, 9a modified apoptotic response and
increased the expression levels of p53, p21, p27, Bax and caspase-3, while it reduced expression levels
of Bcl-2, Mdm-2 and Akt. Additionally, 9a induced the release of cytochrome c from mitochondria
to cytoplasm while it has no significant effect on death-receptor related proteins FAS, procaspase-8
and caspase-8. Collectively, these results suggest that intrinsic (mitochondria) dependent pathways
contributed to 9a-provoked apoptotic death in MCF-7 cells. Moreover, the expression of β-catenin and
phospho AKT was downregulated by 9a. Additionally, compound 9a was found to significantly inhibit
the expression of MMP-9 and VEGF. Finally, the observed data suggest that the 3-cyano-2-substituted
alkoxypyridine moiety might be a potential scaffold for further development of more potent anticancer
agents and compound 9a might be a promising novel therapeutic agent with anti-metastatic activities
in breast cancer.
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